Join ACCP

 
Grants & Funding Opportunities

As part of ACCP's ongoing commitment to Members, we will routinely post appropriately aligned Grants & Funding Opportunities from a variety of sources. Information will be updated in a timely manner and we encourage Members to visit this link frequently for up-to-date information on valuable funding sources. Members are welcome to recommend additional links for posting by forwarding the information to Info@ACCP1.org.

Alzheimer's Drug Discovery Foundation Invites Letters of Intent for Biomarker-Based Clinical Trials in Humans

Many treatments for Alzheimer’s disease have been shown to be safe and to have some positive effect in animal models. However, many of these potentially successful drugs have not been brought to human trial because of the increased cost and risk at that stage of research.

The Alzheimer's Drug Discovery Foundation is responding to this problem with the Alzheimer’s Program to Accelerate Clinical Trials. The goal of the program is to increase the number of innovative drugs for Alzheimer’s disease tested in humans. To that end, grants of up to $1.5 million will be awarded for biomarker-based pilot clinical trials.

Applications may be submitted by nonprofit academic institutions and for-profit biotechnology companies — both public and private - anywhere in the world.

Letters of Intent must be received no later than November 21, 2014. Upon review, selected applicants will be invited to submit full applications, which will be due December 5, 2014.

Deadline Nov 21, 2014

SVS Foundation Announces Vascular Disease Clinical Research Seed Grant Program

The SVS Foundation, the charitable arm of the Society for Vascular Surgery, has announced the launch of the Clinical Research Seed Grant program.

Designed to recognize the importance of clinical investigation in vascular disease, the new program is designed to encourage the interest and development of clinical investigators among the SVS membership, particularly junior members or those with limited prior experience as principal investigators; and to provide direct support for pilot clinical projects that have potential to develop into larger studies fundable by industry or governmental sources.

Clinical research projects, preferably patient-oriented (research conducted with human subjects or on material of human origin such as tissues, specimens and cognitive phenomena for which an investigator directly interacts with human subjects), are eligible for the grant. Applications addressing one of the SVS Clinical Research Priorities are particularly encouraged. Small-scale clinical trials and ancillary studies in the setting of existing clinical trials (industry or NIH-supported) will be accepted.

Grants of up to $15,000 will be awarded for direct costs for a one-year period. Costs for laboratory assays, imaging studies (as appropriate), data collection, and statistical support are allowable. However, principal investigator salary, institutional overhead expenses, major equipment costs, and travel expenses are not allowed.

Deadline Dec 15, 2014

ALS Association Issues RFP for Phase II Clinical Development of Novel Treatments

The ALS Association has announced a Request for Proposals for phase II clinical trials for novel, high-potential treatments for amyotrophic lateral sclerosis, also known as Lou Gehrig’s disease.

The goal of this RFP is to expedite the process of bringing new treatments forward for testing in people with ALS and to measure whether a therapeutic agent is reaching its target. In the United States, ALS affects one in approximately 30,000 people, with 5,000 new diagnoses each year. There is currently one FDA-approved treatment for ALS, Riluzole (Rilutek), which was introduced in the early 1990s.

Grants of up to $1.5 million will be awarded for phase II clinical trials that include therapeutic interventions that have a pharmacodynamics marker that can measure whether the pathway of interest has been affected as well as a plan to collect samples for biomarker studies.

The program is open to academic-industry partnerships, including pharmaceutical, biotherapeutic/biotechnology companies, academic members of the NEALS Consortium, and ALS scientists around the world. Funding will cover direct costs only.

Deadline Letters of Intent Jan 9, 2015

Clinical Studies of Safety and Effectiveness of Orphan Products Research Project Grant (R01)

The application due dates are February 4, 2015; February 3, 2016; February 1, 2017; and February 7, 2018

The Food and Drug Administration (FDA) is announcing the availability of grant funds for the support of FDA's Office of Orphan Products Development grant program. The goal of FDA's Orphan Products Development (OPD) grant program is to support the clinical development of products for use in rare diseases or conditions where no current therapy exists or where the proposed product will be superior to the existing therapy. FDA provides grants for clinical studies on safety and/or effectiveness that will either result in, or substantially contribute to, market approval of these products. Applicants must include in the application's Background and Significance section documentation to support the assertion that the product to be studied meets the statutory criteria to qualify for the grant and an explanation of how the proposed study will either help support product approval or provide essential data needed for product development.

Grant funding opportunities at the National Institutes of Health can be found at http://grants.nih.gov/grants/guide/. To Subscribe to the NIH Guide LISTSERV, send an e-mail to listserv@list.nih.gov with the following text in the message body (not the "Subject" line):
subscribe NIHTOC-L your name
(Example: subscribe NIHTOC-L Bill Jones)

Your e-mail address will be automatically obtained from the e-mail message and add you to the LISTSERV.

Grant opportunities from the Substance Abuse and Mental Health Administration:
http://www.samhsa.gov/samhsa_news/volumexvi_1/article5.htm

www.Grants.gov provides information on funding opportunities across all US Federal agencies:

Grant opportunities from the Alzheimer's Drug Discovery Foundation:
http://www.alzdiscovery.org/index.php/research-programs/grant-opportunities

CenterWatch offers several easy-to-search resources on drugs in various stages of development and approval:
http://www.centerwatch.com/drug-information/



21750 Red Rum Drive, Suite 137, Ashburn, VA  20147    Mailing address: PO Box 1758, Ashburn, VA  20146
571-291-3493     Fax: 571-918-4167     Contact Us
Home     About ACCP     Member Login     Healthcare Professionals
Continuing Education     Meetings     Publications     Public Policy     Student Outreach

Site Map | Site contents © 2014 ACCP